CAMBRIDGE, Mass., June 20, 2017 /PRNewswire/ -- Brammer Bio ("Brammer") announces Mr. Christopher Murphy has joined the company as its Chief Manufacturing Officer. Chris brings a wealth of commercial biologics manufacturing, viral vector development, and clinical manufacturing experience to Brammer as the company launches its commercial gene therapy manufacturing operation in Cambridge, MA, and expands its clinical capacity in Alachua, FL.
Chris has more than 25 years of operational and leadership experience in biopharmaceuticals, with expertise in manufacturing, process development, facility design, and quality systems. Chris joins Brammer after 16 years at Sanofi-Genzyme, where he most recently held the position of General Manager of the Allston Landing commercial biologics facility in Boston, MA. Prior to that, Chris developed manufacturing processes and analytical methods for Adenovirus and Adeno-associated virus gene therapy vectors in Framingham, MA, and established Sanofi-Genzyme's clinical gene therapy facility in San Diego, CA, before moving to Boston in 2009.
"We are thrilled to have Chris join Brammer at this key time of our growth. Chris brings a unique blend of commercial and clinical manufacturing experience with deep gene therapy knowledge and an outstanding leadership ethos that will strengthen Brammer's presence as the best in class gene therapy CDMO," said Mark Bamforth, Brammer's President and CEO.
Chris started his career at American Cyanamid (now Pfizer) in Pearl River, NY, where he held positions in quality control, viral vaccine development, and bulk manufacturing. He later joined BioReliance in Rockville, MD, with responsibility for US contract manufacturing operations, focused primarily on viral vector manufacturing and cell banking in support of gene therapy pre-clinical and clinical studies.
Regarding joining Brammer, Chris shared, "I am passionate about the gene therapy industry and excited to be joining the leading gene therapy CDMO. Gene therapy will improve lives and transform healthcare in the coming years. Brammer is uniquely positioned with exceptional scientific know-how and top class manufacturing and quality operations. I am delighted to join a team that has honed its expertise through the delivery of over 150 clinical batches and is now preparing to supply phase III and commercial gene therapy products for clients."
"Chris's experience manufacturing viral vectors and his understanding of their quality attributes together with his commercial manufacturing track record is unique. He is a great addition to our team," noted Richard Snyder, Ph.D., Brammer's CSO.
Chris holds a Bachelor's degree in Biological Sciences from Rutgers University – Cook College and a Master's degree in Biochemistry from New York Medical College. Chris is active in the community including serving as Vice Chairman, Board of Directors for Massachusetts Biotechnology Education Foundation and on the Board of Directors for the West End House Boys and Girls Club of Boston.
Brammer Bio is a leading CDMO providing clinical and commercial supply of vectors for in vivo gene therapy and ex vivo modified-cell based therapy, along with process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patients' health. Brammer is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders. For more information, please visit www.brammerbio.com
SOURCE Brammer Bio